Navigation Links
Multiferon Shows Potent Activity in Preventing the Progression of,Malignant Melanoma; Study to be Published

PLANTATION, Fla., May 08, 2007 /PRNewswire-FirstCall/ -- Viragen, Inc. and Viragen International, Inc. today announced results from a sponsored in vitro study conducted at Umea University in Sweden, which found that Multiferon(R) (multi- subtype, human alpha interferon) suppressed development of resistant human melanoma clones to a far greater degree than recombinant alpha interferon. The study has been accepted for publication in AntiCancer Research, International Journal of Cancer Research and Treatment.

The study, conducted by Professor Erik Lundgren, Head of Research at the Department of Molecular Biology, Umea University, was designed to compare Multiferon(R) and Intron(R) A* (Interferon alpha-2b, recombinant) with respect to the abilities of each product to inhibit the development of interferon- resistant melanoma cells in vitro, in order to better understand the reason for melanoma treatment failures.

The Study:

Three human melanoma cell lines were grown at a range of different cell concentrations in the presence of graded doses of either Multiferon(R) or Intron(R) A. After four weeks, the number of melanoma cell colonies were assessed and their properties analyzed.

Results:

Long-term treatment with Multiferon(R) was found to result in substantially fewer interferon-resistant melanoma clones than treatment with Intron(R) A. When treated with the single-subtype, recombinant alpha interferon, not only were distinct colonies found, but scattered individual cells were also observed. In contrast, during short term treatment, there was no difference in potency between the two interferon types with respect to growth and survival.

Conclusion:

The results suggest that the mixture of six human alpha subtypes present in Multiferon(R) (a1 a2, a8, a10, a14, a21) provides distinct benefits versus other alpha interferon products in vitro with respect to reducing the numb er of resistant clones.

According to Professor Lundgren, "It is widely known that melanoma cells often develop resistance to recombinant alpha interferon therapies. We observed dramatically different outcomes when comparing Multiferon(R) against Intron(R) A in human melanoma cell lines in vitro, with Multiferon(R) clearly suppressing resistance development far more efficiently than Intron(R) A after four weeks of treatment. One possibility is that multiple subtypes of alpha interferon in Multiferon(R) are working synergistically to eradicate resistant cell clones. If Multiferon(R) is indeed suppressing the development of resistant melanoma clones, this effect may have played a role in improving overall survival in melanoma patients in Viragen's previously reported Phase II/III melanoma trial, published last year in Acta Oncologica."

In February 2006, Multiferon(R) was approved in Sweden for the first-line adjuvant treatment of high-risk malignant melanoma. Viragen is preparing to proceed with a European Union (EU) regulatory process for Multiferon(R), through a registration pathway called the Mutual Recognition Procedure (MRP). This procedure allows a single registration dossier to be filed for approval among a targeted group of EU countries via one application and review process.

* Intron(R) A is registered trademark of Schering-Plough Corporation

About Malignant Melanoma:

Skin cancer is the most common type of cancer, accounting for more than 50% of all cancers. Melanoma accounts for approximately 4% of skin cancer cases, but causes 79% of skin cancer deaths. The American Cancer Society estimates that in 2006 there were 62,190 new cases of melanoma in the United States and about 7,910 people died of this disease.

About Multiferon(R):

Alpha interferon is produced by the human immune system and helps improve the body's natural resistance to disease.

Multiferon(R) differs from single-subtype recombinant alpha in terferon drug products in that it contains a unique mixture of multiple subtypes of human interferon (a1, a2, a8, a10, a14, a21). It is believed that each subtype, some of which are glycosylated, employs a specific biological activity, but more importantly, the subtypes act synergistically to elicit an overall effect.

For prescription information, please visit: http://www.Multiferon.com

About Viragen, Inc.:

With international operations in the U.S., Scotland and Sweden, we are a bio-pharmaceutical company engaged in the research, development, manufacture and commercialization of therapeutic proteins for the treatment of cancers and viral diseases. Our product portfolio includes: Multiferon(R) (multi- subtype, human alpha interferon) which is uniquely positioned in valuable niche indications, such as high-risk malignant melanoma, and other select cancers and infectious diseases; VG102, a novel monoclonal antibody that binds selectively to an antigen that is significantly over-expressed on nearly all malignant tumors; and VG106, a novel cytokine targeting difficult-to-treat cancers. We are also pioneering the development of The OVA(TM) System with the renowned Roslin Institute, creators of "Dolly the Sheep", as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies, by expressing these products in the egg whites of transgenic hens.

          For more information, please visit: http://www.Viragen.com


    Viragen, Inc. Corporate Contact:

    Douglas Calder, Director of Communications

    Phone: (954) 233-8746; Fax: (954) 233-1414

    E-mail: 

dcalder@viragen.com

The foregoing press announcement contains forward-looking statements that can be identified by such terminology s uch as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the success of third- party marketing efforts; our ability to retain third-party distributors; our ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.

CONTACT: Douglas Calder, Director of Communications of Viragen, Inc.,+1-954-233-8746, Fax, +1-954-233-1414, dcalder@viragen.com

Web site: http://www.viragen.com//

Ticker Symbol: (AMEX:VRA),(NASDAQ-OTCBB:VGNI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- A Small Business Innovative Research (SBIR) grant has ... to Phoenix -based NeuroEM Therapeutics, Inc. ... will seek to determine an optimal set of treatment ... to treat Alzheimer,s Disease. The grant will also investigate ... other neurologic disorders such as Parkinson,s Disease and PTSD. ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
(Date:12/8/2016)... 8, 2016 According to ... by Product (Actual Sugars, Sugar Alcohols, Artificial Sweeteners), ... Tonicity Agents), Formulation (Oral, Topical, Parenteral) - Global ... has witnessed healthy growth during the last decade, ... of 4.3% between 2016 and 2021 to reach ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... California Senate Bill (SB) 863, signed into law in 2012, ... and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , a ... study, medical payments per claim in California decreased 4 percent in 2013 and then ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne ... offices headquartered in Hamilton County, is embarking on a charity drive with the ... finding new homes for orphaned or neglected senior dogs in the Cincinnati region, ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial consulting services to residential and commercial clients in the northern Alabama ... support for Nobis Works. , Since 1977, Nobis Works has built a network ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting ... MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone in ... it’s needed. , A 2’ x 4’ model features four modes: reading, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... (“Presence”) for a purchase price of approximately $17.4 million (net of the ... revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is a ...
Breaking Medicine News(10 mins):